JMS (7702) Fundamentals 2026 — Revenue Analysis | SniperIQ
JMS (7702) is a JP-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥11.5B, trading at ¥468.00 on the JPX. This SniperIQ fundamentals page covers JMS's valuation, profitability (net margin -1.2%), revenue (¥65.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is JMS's market cap?
JMS (7702) has a market capitalization of approximately ¥11.5B, trading at ¥468.00 on the JPX. Market cap moves with the live share price.
What is JMS's P/E ratio?
JMS's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is JMS?
JMS runs a net profit margin of -1.2%, a gross margin of 23.3%, and an operating margin of 0.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does JMS generate?
JMS reported revenue of ¥65.8B for fiscal year 2025, with net income of -¥784M and earnings per share (EPS) of -31.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does JMS pay a dividend?
JMS offers a trailing dividend yield of about 3.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is JMS financially healthy?
JMS carries a debt-to-equity ratio of 0.67x and a current ratio of 1.78x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is JMS a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JMS (7702) the key facts are: market cap ¥11.5B, revenue ¥65.8B, 52-week range 418-478. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track JMS's full fundamentals live
Get JMS's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.